CATXPerspective Therapeutics, Inc.Healthcare · Medical - Devicesas of 2026-09-16
Horizon

Issued 2026-09-16 at $2.70 · now $2.70 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, CATX has typically landed between $1.83 and $3.98 — a range of −32.1% to +47.4% from the issuance price $2.70.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,993 overlapping 1 month windows · 2006-09-262026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.70) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CATX has typically landed a month from the 2026-09-16 close of $2.7 — the range is history, not a prediction.

$1.83worst · -32.1%$3.98best · +47.4%
  • now $2.7 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.61 (-3.3%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.18$3.04
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.83$3.98
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,993 windows spanning 2006-09-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-10-23−74.3%−74.3%+5.6%
2024-10-24−70.8%−74.8%+3.8%
2024-11-05−69.9%−75.7%+0.0%
3 best
2009-07-17+565.3%−7.3%+565.3%
2020-12-15+476.6%+0.0%+476.6%
2009-07-20+466.7%−4.2%+587.5%

4,993 overlapping windows · 2006-09-262026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
65%
+30.8%
n=20
Feb
35%
−3.7%
n=20
Mar
45%
+8.6%
n=20
Apr
60%
+10.3%
n=20
May
45%
+3.4%
n=20
Jun
35%
−1.9%
n=20
Jul
45%
+6.4%
n=20
Aug
40%
+6.5%
n=20
Sep
20%
−10.5%
n=20
Oct
25%
−7.4%
n=20
Nov
30%
−1.8%
n=20
Dec
35%
−5.8%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$6$22026-09-04: 1 insider sale, $526K — Lantheus Alpha Therapy, LLC2026-09-03: 1 insider sale, $251K — Lantheus Alpha Therapy, LLC2026-09-02: 1 insider sale, $131K — Lantheus Alpha Therapy, LLC2026-09-01: 2 insider sales, $223K — Lantheus Holdings, Inc., Lantheus Alpha Therapy, LLC2026-08-31: 2 insider sales, $491K — Lantheus Alpha Therapy, LLC, Lantheus Holdings, Inc.2025-11-13: 1 insider purchase, $22K — Hunt Jonathan Robert2025-11-12: 1 insider purchase, $20K — Williamson Robert F III2025-11: 2 open-market purchases, $42K2026-08: 2 open-market sales, $491K2026-09: 5 open-market sales, $1.1M↑ buys↓ salestenPercentOwner Lantheus Alpha Therapy, LLC — Sale on 2026-09-04, filed 4 days after the tradetenPercentOwner Lantheus Alpha Therapy, LLC — Sale on 2026-09-03, filed 5 days after the tradetenPercentOwner Lantheus Alpha Therapy, LLC — Sale on 2026-09-02, filed 2 days after the tradetenPercentOwner Lantheus Holdings, Inc. — Sale on 2026-09-01, filed 2 days after the tradetenPercentOwner Lantheus Alpha Therapy, LLC — Sale on 2026-09-01, filed 3 days after the tradetenPercentOwner Lantheus Alpha Therapy, LLC — Sale on 2026-08-31, filed 4 days after the tradetenPercentOwner Lantheus Holdings, Inc. — Sale on 2026-08-31, filed 2 days after the tradeofficer Hunt Jonathan Robert — Purchase on 2025-11-13, filed 4 days after the tradedirector Williamson Robert F III — Purchase on 2025-11-12, filed 2 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-09-04Lantheus Alpha Therapy, LLCtenPercentOwnerSale167,149 @ $3.15$526K−1.5% of holdingnot yet — horizon still opennot yet — horizon still open11,273,364Form 4 · filed 4 days after the trade
2026-09-03Lantheus Alpha Therapy, LLCtenPercentOwnerSale80,783 @ $3.11$251K−0.7% of holdingnot yet — horizon still opennot yet — horizon still open11,440,513Form 4 · filed 5 days after the trade
2026-09-02Lantheus Alpha Therapy, LLCtenPercentOwnerSale42,129 @ $3.11$131K−0.4% of holdingnot yet — horizon still opennot yet — horizon still open11,521,296Form 4 · filed 2 days after the trade
2026-09-01Lantheus Holdings, Inc.tenPercentOwnerSale35,769 @ $3.12$112K−0.3% of holdingnot yet — horizon still opennot yet — horizon still open11,563,425Form 4 · filed 2 days after the trade
2026-09-01Lantheus Alpha Therapy, LLCtenPercentOwnerSale35,769 @ $3.12$112K−0.3% of holdingnot yet — horizon still opennot yet — horizon still open11,563,425Form 4 · filed 3 days after the trade
2026-08-31Lantheus Alpha Therapy, LLCtenPercentOwnerSale78,145 @ $3.14$246K−0.7% of holdingnot yet — horizon still opennot yet — horizon still open11,599,194Form 4 · filed 4 days after the trade
2026-08-31Lantheus Holdings, Inc.tenPercentOwnerSale78,145 @ $3.14$246K−0.7% of holdingnot yet — horizon still opennot yet — horizon still open11,599,194Form 4 · filed 2 days after the trade
2025-11-13Hunt Jonathan RobertofficerPurchase11,000 @ $2.03$22K+22.5% of holding+21.4%+65.6%59,800Form 4 · filed 4 days after the trade
2025-11-12Williamson Robert F IIIdirectorPurchase9,498 @ $2.10$20K+2595.1% of holding+26.2%+68.7%9,864Form 4 · filed 2 days after the trade
2025-03-31Williamson Robert F IIIdirectorPurchase38,145 @ $2.14$82K+53.8% of holding+15.9%+41.3%108,982Form 4 · filed 1 day after the trade
2025-03-31Woods Lori AdirectorPurchase23,475 @ $2.13$50K+14.7% of holding+15.9%+41.3%183,460Form 4 · filed 1 day after the trade
2025-03-28Graham JuanofficerPurchase33,333 @ $2.25$75K+1649.3% of holding+9.8%+32.1%35,354Form 4 · filed 4 days after the trade
2025-03-28Williamson Robert F IIIdirectorPurchase22,192 @ $2.27$50K+45.6% of holding+9.8%+32.1%70,837Form 4 · filed 4 days after the trade
2025-03-28Spoor Johan M.directorPurchase22,026 @ $2.24$49K+59.0% of holding+9.8%+32.1%59,383Form 4 · filed 4 days after the trade
2025-03-28Spoor Johan M.directorPurchase4,650 @ $2.21$10Kownership Δ n/a+9.8%+32.1%4,650Form 4 · filed 4 days after the trade
2024-12-04HENSON HEIDIdirectorPurchase25,975 @ $3.85$100Kownership Δ n/a−3.2%−12.3%25,975Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

18 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-03-02Puhlmann MarkusofficerAward / grant150,000150,000Form 4
2026-03-02Hunt Jonathan RobertofficerAward / grant90,00090,000Form 4
2026-03-02HENSON HEIDIdirectorAward / grant50,00050,000Form 4
2026-03-02Woods Lori AdirectorAward / grant50,00050,000Form 4
2026-03-02Williamson Robert F IIIdirectorAward / grant50,00050,000Form 4
2026-03-02Spoor Johan M.directorAward / grant735,000735,000Form 4
2026-03-02Morich FrankdirectorAward / grant50,00050,000Form 4
2026-03-02Martinez Maria EdirectorAward / grant50,00050,000Form 4
2025-09-04Sendek JoelofficerAward / grant600,000600,000Form 4
2025-09-03Martinez Maria EdirectorAward / grant75,00075,000Form 4
2025-03-03Spoor Johan M.directorAward / grant650,000650,000Form 4
2025-03-03Puhlmann MarkusofficerAward / grant165,000165,000Form 4
2025-03-03Williamson Robert F IIIdirectorAward / grant50,00050,000Form 4
2025-03-03HENSON HEIDIdirectorAward / grant50,00050,000Form 4
2025-03-03Hunt Jonathan RobertofficerAward / grant75,00075,000Form 4
2025-03-03Woods Lori AdirectorAward / grant50,00050,000Form 4
2025-03-03Morich FrankdirectorAward / grant50,00050,000Form 4
2025-01-06Graham JuanofficerAward / grant400,000400,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.